Blog – Page 631

FDA Approves Lilly and Incyte’s OLUMIANT (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata

By ApoThera June 19, 2022Blog

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib), a once-daily pill, as a first-in-disease systemic treatment…

Risankizumab (SKYRIZI) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn’s Disease in Adults

By ApoThera June 19, 2022Blog

Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely active Crohn's disease,…

FDA Approves Fylnetra (pegfilgrastim-pbbk), Biosimilar to Neulasta (pegfilgrastim), for Treating Neutropenia

By ApoThera June 12, 2022Blog

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a…

FDA Approves Dermavant’s VTAMA (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in Adults

By ApoThera June 11, 2022Blog

FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years EFFICACY: In…

Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients

By ApoThera June 11, 2022Blog

GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older GSK plc (LSE/NYSE: GSK) today announced that…

COVID-19 Variants

By ApoThera June 6, 2022Blog

Put to the test: use of rapid testing technologies for covid-19

By ApoThera June 4, 2022Blog

Put to the test: use of rapid testing technologies for covid-19 BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n208 (Published 03 February 2021)Cite this as: BMJ 2021;372:n208 British Medical Journal

Timeline for COVID-19 Viral Load and Antibody Response (Rapid Antigen Testing and COVID-19 RT-PCR Testing)

By ApoThera May 14, 2022Blog

FDA Approves Igalmi (Dexmedetomidine) Sublingual Film

By ApoThera April 16, 2022Blog

Drug Info: ApoThera Drug Disease Clinical Support App - Assess vital signs including orthostatic measurements before administering Mild or Moderate Schizophrenia Agitation - 120 mcg SL or BUC x 1 dose…

Drug Information for Paxlovid (Nirmatrelvir-Ritonavir), Oral Medications for the Treatment of Mild-to-Moderate COVID-19, Available on ApoThera Clinical Decision Support Mobile Application

By ApoThera April 9, 2022Blog

Drug Info: ApoThera Drug Disease Clinical Support App Nirmatrelvir-Ritonavir (Paxlovid) - 300 mg nirmatrelvir + 100 mg Ritonavir by mouth twice daily x 5 days - Initiate as soon as…